2. Academic Validation
  3. (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors

(4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors

  • Bioorg Med Chem Lett. 2009 Dec 1;19(23):6645-8. doi: 10.1016/j.bmcl.2009.10.012.
Tomomichi Chonan 1,  Takahiro Oi,  Daisuke Yamamoto,  Miyoko Yashiro,  Daisuke Wakasugi,  Hiroaki Tanaka,  Ayumi Ohoka-Sugita,  Fusayo Io,  Hiroko Koretsune,  Akira Hiratate
Affiliations

Affiliation

  • 1 Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, Saitama-shi, Saitama 331-9530, Japan. tomomichi.chonan@po.rd.taisho.co.jp
PMID: 19853443 DOI: 10.1016/j.bmcl.2009.10.012
Abstract

Acetyl-CoA carboxylases (ACCs), the rate limiting Enzymes in de novo lipid synthesis, play important roles in modulating energy metabolism. The inhibition of ACC has demonstrated promising therapeutic potential for treating obesity and type 2 diabetes mellitus in transgenic mice and preclinical animal models. We describe herein the synthesis and structure-activity relationships of a series of disubstituted (4-piperidinyl)-piperazine derivatives as a new platform for ACC1/2 non-selective inhibitors.

Figures